Patents by Inventor Patrick Miossec

Patrick Miossec has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250134964
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: December 19, 2024
    Publication date: May 1, 2025
    Inventors: Elisabeth NIEMOELLER, Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
  • Publication number: 20230028588
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: May 9, 2022
    Publication date: January 26, 2023
    Inventors: Elisabeth Niemoeller, Isabel Muehlen-Bartmer, Louise Silvestre, Gabor Boka, Patrick Miossec
  • Publication number: 20220347269
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: March 15, 2022
    Publication date: November 3, 2022
    Inventors: Elisabeth NIEMOELLER, Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
  • Publication number: 20220054594
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Application
    Filed: July 1, 2021
    Publication date: February 24, 2022
    Inventors: Gabor Boka, Patrick Miossec, Louise Silvestre
  • Publication number: 20200353054
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Application
    Filed: December 13, 2019
    Publication date: November 12, 2020
    Inventors: Gabor Boka, Patrick Miossec, Louise Silvestre
  • Publication number: 20200338171
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: December 26, 2019
    Publication date: October 29, 2020
    Inventors: Elisabeth NIEMOELLER, Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
  • Publication number: 20200330559
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: January 29, 2020
    Publication date: October 22, 2020
    Inventors: Elisabeth Niemoeller, Isabel Muehlen-Bartmer, Louise Silvestre, Gabor Boka, Patrick Miossec
  • Publication number: 20190134160
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: July 18, 2018
    Publication date: May 9, 2019
    Inventors: Elisabeth Niemoeller, Isabel Muehlen-Bartmer, Louise Silvestre, Gabor Boka, Patrick Miossec
  • Publication number: 20190054146
    Abstract: A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and (b) metformin or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: February 21, 2019
    Inventors: Louise Silvestre, Gabor Boka, Patrick Miossec
  • Publication number: 20190030132
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Application
    Filed: April 24, 2018
    Publication date: January 31, 2019
    Inventors: Gabor Boka, Patrick Miossec, Louise Silvestre
  • Publication number: 20180339023
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: April 23, 2018
    Publication date: November 29, 2018
    Inventors: Elisabeth NIEMOELLER, Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
  • Patent number: 9981013
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: May 29, 2018
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Gabor Boka, Patrick Miossec, Louise Silvestre
  • Publication number: 20180000902
    Abstract: A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and (b) a sulfonyl urea or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.
    Type: Application
    Filed: January 20, 2017
    Publication date: January 4, 2018
    Inventors: Gabor Boka, Louise Silvestre, Patrick Miossec
  • Patent number: 9821032
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: November 21, 2017
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Elisabeth Niemoeller, Louise Silvestre, Gabor Boka, Patrick Miossec
  • Publication number: 20170143801
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Application
    Filed: February 13, 2017
    Publication date: May 25, 2017
    Inventors: Elisabeth NIEMOELLER, Isabel MUEHLEN-BARTMER, Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
  • Publication number: 20170119852
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Application
    Filed: January 23, 2017
    Publication date: May 4, 2017
    Inventors: Gabor BOKA, Patrick MIOSSEC, Louise SILVESTRE
  • Publication number: 20170080057
    Abstract: A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and (b) metformin or/and a pharmaceutically acceptable salt thereof, to a subject in need thereof.
    Type: Application
    Filed: May 2, 2016
    Publication date: March 23, 2017
    Inventors: Louise SILVESTRE, Gabor BOKA, Patrick MIOSSEC
  • Patent number: 9408893
    Abstract: The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: August 9, 2016
    Assignee: Sanofi-Aventis Deutschland GMBH
    Inventors: Elisabeth Niemöeller, Isabel Müehlen-Bartmer, Louise Silvestre, Gabor Boka, Patrick Miossec
  • Publication number: 20140148384
    Abstract: The present invention refers to the use of Lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Application
    Filed: August 30, 2010
    Publication date: May 29, 2014
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Gabor Boka, Patrick Miossec, Louise Silvestre
  • Patent number: 8735349
    Abstract: The present invention refers to a pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: May 27, 2014
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Louise Silvestre, Gabor Boka, Patrick Miossec